Stephen F. Mahoney - 02 Mar 2026 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role: President and CEO
Signature: Jennifer Tousignant, Attorney-in-fact
Issuer symbol: VRDN
Transactions as of: 02 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 04 Mar 2026, 18:56:17 UTC
Previous filing: 04 Mar 2025
Next filing: 09 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Mahoney Stephen F.	President and CEO	C/O VIRIDIAN THERAPEUTICS, INC., 221 CRESCENT STREET, SUITE 103A, WALTHAM	Jennifer Tousignant, Attorney-in-fact	04 Mar 2026	0001741389

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VRDN	Common Stock	Options Exercise		+18,357	+82%		40,757	03 Mar 2026	Direct	F2, F5
transaction	VRDN	Common Stock	Tax liability		-7,627	-19%	$29.32^*	33,130	03 Mar 2026	Direct	F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VRDN	Stock Option (Right to Buy)	Award		+559,600		$0.000000^*	559,600	02 Mar 2026	Common Stock	559,600	$30.25	Direct	F1
transaction	VRDN	Restricted Stock Units	Award		+111,900		$0.000000^*	111,900	02 Mar 2026	Common Stock	111,900		Direct	F2, F3
transaction	VRDN	Restricted Stock Units	Options Exercise		-18,357	-25%	$0.000000^*	55,071	03 Mar 2026	Common Stock	18,357		Direct	F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 2, 2026.
F2	Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.
F3	The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.
F4	The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date.
F5	Includes 1,000 shares acquired under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan (the "ESPP") on March 17, 2025 in transactions that were exempt under Rule 16b-3(c).